| scholarly article | Q13442814 |
| P2093 | author name string | Michael Y Gerner | |
| Matthew F Mescher | |||
| Kerry A Casey | |||
| P2860 | cites work | CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. | Q24540429 |
| Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation | Q24677534 | ||
| Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity | Q28138211 | ||
| Cancer despite immunosurveillance: immunoselection and immunosubversion | Q28263865 | ||
| Differential antigen processing by dendritic cell subsets in vivo | Q29615177 | ||
| Immunosuppressive networks in the tumour environment and their therapeutic relevance | Q29619244 | ||
| Dendritic cells program non-immunogenic prostate-specific T cell responses beginning at early stages of prostate tumorigenesis. | Q33756652 | ||
| Initial T cell frequency dictates memory CD8+ T cell lineage commitment | Q33768584 | ||
| Autophagy promotes MHC class II presentation of peptides from intracellular source proteins | Q33841180 | ||
| Cell biology of antigen processing in vitro and in vivo | Q33985828 | ||
| Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory | Q34190038 | ||
| CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. | Q34339494 | ||
| Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity | Q34357808 | ||
| Initial T cell receptor transgenic cell precursor frequency dictates critical aspects of the CD8(+) T cell response to infection. | Q36008100 | ||
| In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor | Q36229738 | ||
| CD8alpha+ and CD8alpha- subclasses of dendritic cells direct the development of distinct T helper cells in vivo | Q36367705 | ||
| Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function | Q36370978 | ||
| Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. | Q36371632 | ||
| Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation | Q36376648 | ||
| Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression | Q36399807 | ||
| Dendritic cells in a mature age. | Q36475977 | ||
| Signals required for programming effector and memory development by CD8+ T cells | Q36528952 | ||
| Inflaming the CD8+ T cell response. | Q36543883 | ||
| Cellular protein is the source of cross-priming antigen in vivo | Q36853548 | ||
| Signal 3 availability limits the CD8 T cell response to a solid tumor | Q40130393 | ||
| Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. | Q40212541 | ||
| A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL. | Q40553918 | ||
| CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes | Q40669542 | ||
| Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma | Q40774007 | ||
| Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors | Q42029476 | ||
| CD4+ T cells can protect APC from CTL-mediated elimination | Q44678363 | ||
| Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania | Q44920559 | ||
| The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles | Q48914128 | ||
| Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. | Q51983318 | ||
| Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo. | Q52003804 | ||
| Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide. | Q53640046 | ||
| CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism | Q56906680 | ||
| Cutting Edge: Precursor Frequency Affects the Helper Dependence of Cytotoxic T Cells | Q57227884 | ||
| Cell-Associated Ovalbumin Is Cross-Presented Much More Efficiently than Soluble Ovalbumin In Vivo | Q57227930 | ||
| Cutting Edge: Intravenous Soluble Antigen Is Presented to CD4 T Cells by CD8- Dendritic Cells, but Cross-Presented to CD8 T Cells by CD8+ Dendritic Cells | Q57227937 | ||
| Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication | Q58234979 | ||
| Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation | Q73202999 | ||
| Dendritic cell longevity and T cell persistence is controlled by CD154-CD40 interactions | Q73592527 | ||
| Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity | Q73691187 | ||
| Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets | Q73785333 | ||
| Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression | Q74330354 | ||
| Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage | Q77787494 | ||
| Dendritic cells cross-dressed with peptide MHC class I complexes prime CD8+ T cells | Q79287424 | ||
| Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer | Q79609573 | ||
| IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype | Q80427899 | ||
| Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors | Q80444910 | ||
| Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation | Q81621807 | ||
| CD4 T cell-dependent conditioning of dendritic cells to produce IL-12 results in CD8-mediated graft rejection and avoidance of tolerance | Q81767220 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 155-164 | |
| P577 | publication date | 2008-07-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses | |
| P478 | volume | 181 |
| Q37267598 | Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells |
| Q40216461 | Assessment of changes in expression and presentation of NKG2D under influence of MICA serum factor in different stages of breast cancer. |
| Q64260954 | Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity |
| Q48185876 | CD4 and CD8 T lymphocyte interplay in controlling tumor growth |
| Q85232812 | CD4+ T cell response against a non-tumor antigen is unaffected in melanoma-bearing mice |
| Q84015414 | CD8alpha+ DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor |
| Q91638872 | CTL-Derived Exosomes Enhance the Activation of CTLs Stimulated by Low-Affinity Peptides |
| Q37832967 | Contribution of the immune system to the chemotherapeutic response. |
| Q37760422 | Cross-priming in health and disease. |
| Q36468274 | Cytotoxic effector function of CD4-independent, CD8(+) T cells is mediated by TNF-α/TNFR. |
| Q38994017 | Dendritic Cells and Cancer Immunity. |
| Q38059514 | Dendritic cell-based immunotherapy in mesothelioma |
| Q37960189 | Developing dendritic cell-based therapies to condition immune responses to novel oncogenic proteins and stem cells |
| Q92792643 | Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade |
| Q34419349 | Ex vivo development, expansion and in vivoanalysis of a novel lineage of dendritic cells from hematopoietic stem cells |
| Q39201713 | HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance |
| Q40449413 | IL-1βR-dependent priming of antitumor CD4(+) T cells and sustained antitumor immunity after peri-tumoral treatment with MSU and mycobacteria. |
| Q26798402 | Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites |
| Q47601017 | Induction of T cell responses and recruitment of an inflammatory dendritic cell subset following tumor immunotherapy with Mycobacterium smegmatis |
| Q47113436 | Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer |
| Q49072169 | Lung tumours reprogram pulmonary dendritic cell immunogenicity at the microRNA level |
| Q38918609 | Molecular mechanisms involved in dendritic cell dysfunction in cancer |
| Q28386617 | Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells |
| Q34749303 | OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence |
| Q28384581 | Oxidized lipids block antigen cross-presentation by dendritic cells in cancer |
| Q38710878 | Prediction of Radix Astragali Immunomodulatory Effect of CD80 Expression from Chromatograms by Quantitative Pattern-Activity Relationship |
| Q39398295 | Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses |
| Q35209044 | Strengthened tumor antigen immune recognition by inclusion of a recombinant Eimeria antigen in therapeutic cancer vaccination |
| Q92404807 | Striking a Balance-Cellular and Molecular Drivers of Memory T Cell Development and Responses to Chronic Stimulation |
| Q35569843 | The aging immune system and its relationship with cancer |
| Q86839252 | The site of tumor development determines immunogenicity via temporal mobilization of antigen-laden dendritic cells in draining lymph nodes |
| Q38026924 | The use of agonistic anti-CD40 therapy in treatments for cancer |
| Q34210664 | Tumor antigen cross-presentation and the dendritic cell: where it all begins? |
| Q36373352 | Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation |
| Q37598949 | Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses |
| Q45775114 | Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. |
| Q36514324 | Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model |
| Q28395507 | Val-boroPro accelerates T cell priming via modulation of dendritic cell trafficking resulting in complete regression of established murine tumors |
Search more.